Research Studies at ECHN
| Interested in participating in a research study? Please call the Research office at ECHN, (860) 646-2518. |
Many physicians on the ECHN medical staff participate in research studies, also called clinical trials, which test new medications or procedures. Patients may choose to participate in such trials as a way to have access to some newer treatments and as a way to contribute to medical science.
A research study involving human subjects is not conducted unless a medication or procedure is deemed safe enough to use for humans. All studies at ECHN must be approved by the ECHN Institutional Review Committee.
ECHN physicians join leading researchers from around the world in working to bring the latest, leading-edge treatments to market. Here is a list of research studies currently underway at ECHN:
|
PACCT-1 (TAILORx) - Adjuvant Treatment of Breast Cancer with Oncotype DX
|
Breast Cancer |
|
Wyeth 3144A2-3005-WW - A Phase III, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB2-Positive Locally Recurrent or Metastatic Breast Cancer |
Breast Cancer |
|
E2Z04 - Quality of Life in Younger Breast Cancer Survivors |
Breast Cancer |
| CALGB40601 - Randomized Phase III Trial of Paclitaxel combined with Trastuzamab, Lapatinib or both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer |
Breast Cancer |
|
CALGB 10501 - A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention versus Observation with Later Treatment in the High Risk Genetic Subset with IvGh unmated disease |
Leukemia |
|
S0421 - Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer |
Prostate Cancer |
|
E2805 - A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma |
Renal Cancer |
|
E4805 - A Randomized, Phase II Study to Determine the Effect of Two Different Doses of AVE0005 (VGEF Trap) in Patients with Metastatic Renal Cell Carcinoma |
Renal Cancer |
|
*Novartis protocol CSTI5721BUS227, Gastrointestinal Stromal Tumors (GIST) Registry Protocol |
Gastric Cancer |
| CALGB 70604 - A Randomized Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid (Zometa) in Metastatic Cancer |
Breast, Prostate, Multiple Myeloma |
|
|
Updated 02/25/10